中国寄生虫学与寄生虫病杂志 ›› 2012, Vol. 30 ›› Issue (3): 5-184-188.

• 论著 • 上一篇    下一篇

口服阿苯达唑抗小鼠旋毛虫成囊期幼虫的效果观察

李润花1,裴彦江2,李起超2,霍将2,丁宇2,殷国荣3 *   

  1. 1 太原师范学院生物系,太原 030031; 2 山西医科大学七年制临床医学,太原 030001;
    3 山西医科大学寄生虫学教研室,太原 030001
  • 出版日期:2012-06-30 发布日期:2012-09-28

Efficacy of Albendazole Orally Administered at Different Dosages against Trichinella spiralis Encapsulated Larvae in Mice

LI Run-hua1,PEI Yan-jiang2,LI Qi-chao2,HUO Jiang2,DING Yu2,YIN Guo-rong3 *   

  1. 1 Department of Biology,Taiyuan Normal University,Taiyuan 030031,China; 2 Department of Clinical Medicine,Shanxi Medical University,Taiyuan 030001,China; 3 Department of Parasitology,Shanxi Medical University,Taiyuan 030001,China
  • Online:2012-06-30 Published:2012-09-28

摘要: 目的  观察口服不同剂量阿苯达唑抗小鼠旋毛虫成囊期幼虫的效果。  方法  BALB/c小鼠72只,随机均分为9组,每只小鼠口饲感染旋毛虫成囊期幼虫50条。感染后第29天,分别口服阿苯达唑50、100、150、200、250、300、350和400 mg/(kg·d),每天固定时间给药1次,连续6 d。对照组不作处理。停药后第7天,脱颈处死小鼠,肌肉压片法检查小鼠膈肌、咬肌和腓肠肌中幼虫,观察成囊期幼虫存活情况,计算每克肌肉总虫数、活虫数和死虫数,以及总减虫率和活虫减少率,评价各剂量组疗效。  结果  当阿苯达唑剂量为50~250 mg/(kg·d)时,膈肌、咬肌和腓肠肌中成囊期幼虫总虫数和活虫数均随剂量升高呈下降趋势,而死虫数呈上升趋势;但当阿苯达唑剂量大于250 mg/(kg·d)时,3个部位肌肉中虫数不再有明显变化。与对照组相比,200 mg/(kg·d)及以上剂量组3个部位肌肉的总虫数和活虫数均显著减少(均P<0.01),其中250 mg/(kg·d)为治疗肌肉期旋毛虫病的适宜剂量,其膈肌、咬肌和腓肠肌的总减虫率分别为50.00%、62.62%和57.48%,活虫减少率分别为79.96%、83.25%和80.56%。  结论  小鼠连续口服阿苯达唑250 mg/(kg·d)×6 d为其治疗肌肉期旋毛虫病的适宜剂量。

关键词: 阿苯达唑, 旋毛虫, 成囊期幼虫, 疗效, 小鼠

Abstract: Objective   To evaluate the efficacy of albendazole (ABZ) orally administered at different dosages against Trichinella spirails encapsulated larvae in striated muscle in mice.  Methods  A total of 72 BALB/c mice were divided equally into 9 groups. Each mouse was infected orally with 50 T. spiralis encapsulated larvae. At the 29th day after infection, albendazole was each orally administered to the mice of the 8 groups with doses of 50, 100, 150, 200, 250, 300, 350, and 400 mg/(kg·d), respectively, once a day at fixed time for 6 d. The control group was untreated. Mice were sacrificed at the 7th day post administration. The encapsulated larvae in diaphragmatic muscle, jugomaxillary muscle and gastrocnemius muscle were examined with pellet method. The encapsulated larva that the capsule was complete and the larva inside curled naturally with clear structure was considered survived. The therapeutic effect was estimated on the average quantity of total, survival and dead encapsulated larvae per gram muscle, total worm reduction and survival worm reduction.  Results  The total worm burden and survival worms showed a decreasing trend and the numbers of dead worms increased in diaphragmatic muscle, jugomaxillary muscle and gastrocnemius muscle when the dosage of albendazole were 50-250 mg/(kg·d), but the number of larvae in the muscles remained similar when the dosage of albendazole was greater than 250 mg/kg·d. Compared with the control group, the total and survival worms in the muscles in 200 mg/(kg·d) and the greater dose groups decreased significantly (P<0.01). In 250 mg/(kg·d) group the total worm reduction in jugomaxillary muscle, diaphragmatic muscle and gastrocnemius muscle were 50.00%, 62.62% and 57.48%, and the survival worm reduction were 79.96%, 83.25% and 80.56%, respectively.  Conclusion  Orally administered to mice for 6 d, albendazole at 250 mg/(kg·d) is a suitable dose against encapsulated larva stage of T. spiralis in muscle.

Key words: Albendazole, Trichinella spiralis, Encapsulated larva, Efficacy, Mouse